These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17163281)

  • 21. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.
    Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM
    CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. InforMatrix: ADP antagonists in acute coronary syndromes.
    Janknegt R; Ruiters L; Ten Cate H
    Expert Opin Pharmacother; 2012 Feb; 13(3):357-85. PubMed ID: 22220778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Choice of antibiotics in uncomplicated cystitis; application of 'system of objectified judgement analysis' (SOJA) method].
    Janknegt R; van den Broek PJ; Kullberg BJ; Stobberingh E
    Ned Tijdschr Geneeskd; 1999 Dec; 143(49):2466-71. PubMed ID: 10608985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Product standardisation as a tool to control prescribing costs - a case study of alginate liquid preparations.
    Alahdab OG; Crealey G; Scott MG; Mairs J; McElnay JC
    Int J Pharm Pract; 2013 Apr; 21(2):73-81. PubMed ID: 23418744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing costs and improving hypertension management.
    Stankus V; Hemmelgarn B; Campbell NR; Chen G; McAlister FA; Tsuyuki RT
    Can J Clin Pharmacol; 2009; 16(1):e151-5. PubMed ID: 19193969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of angiotensin II receptor blockers for drug formulary using objective scoring analytical tool.
    Lim TM; Ibrahim MI
    Pharm Pract (Granada); 2012 Jul; 10(3):136-42. PubMed ID: 24155829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.
    Mortensen MB
    Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Establishing an enteral product formulary.
    Ford DB; Bergerson SL; Henderson P; Murphy J; Peter J
    J Am Diet Assoc; 1989 May; 89(5):681-3. PubMed ID: 2498416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?
    Sigvant B; Henriksson M; Lundin F; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2011 Apr; 18(2):254-61. PubMed ID: 21450673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing drug formularies for the "National Medical Holding" JSC.
    Akhmadyar NS; Khairulin BE; Amangeldy-Kyzy S; Ospanov MA
    Int J Risk Saf Med; 2015; 27 Suppl 1():S51-2. PubMed ID: 26639709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.
    Fry RN; Avey SG; Sullivan SD
    Value Health; 2003; 6(5):505-21. PubMed ID: 14627057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applying rapid 'de-facto' HTA in resource-limited settings: experience from Romania.
    Lopert R; Ruiz F; Chalkidou K
    Health Policy; 2013 Oct; 112(3):202-8. PubMed ID: 23953877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deciding which drugs get onto the formulary: a value-based approach.
    Seigfried RJ; Corbo T; Saltzberg MT; Reitz J; Bennett DA
    Value Health; 2013; 16(5):901-6. PubMed ID: 23947985
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.